HAMILTON, ON and BOSTON, Nov. 8, 2023
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a
clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision medicines, today
announced that the Company will participate in two upcoming
investor conferences.
- Jefferies London Healthcare Conference – The Company fireside
chat presentation will take place on Thursday, November 16, 2023 at 9:00 a.m. GMT. Presenting on behalf of Fusion
will be Chief Executive Officer John
Valliant, Ph.D.
- Piper Sandler 35th
Annual Healthcare Conference – The Company will participate in the
"Radiopharmaceuticals Panel" taking place on Wednesday, November 29, 2023 at 10:00 a.m. ET. Presenting on behalf of Fusion
will be Chief Scientific Officer Christopher Leamon, Ph.D.
Webcasts of each event will be available on the "Events and
Presentations" page in the "Investors & Media" section of the
Company's website at https://ir.fusionpharma.com/events-webcasts. A
replay of the webcast will be archived on the Company's website for
90 days following their respective presentation dates.
About Fusion
Fusion Pharmaceuticals is a
clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision
medicines. Fusion connects alpha particle emitting isotopes to
various targeting molecules to selectively deliver the alpha
emitting payloads to tumors. Fusion's clinical portfolio includes:
FPI-2265 targeting prostate specific membrane antigen
(PSMA) for metastatic castration resistant prostate
cancer currently in a Phase 2 trial; FPI-1434 targeting
insulin-like growth factor 1 receptor currently in a Phase 1 trial;
and FPI-2059, a small molecule targeting neurotensin
receptor 1 (NTSR1), currently in a Phase 1 trial. In addition
to a robust proprietary pipeline, Fusion has a collaboration
with AstraZeneca to jointly develop novel targeted
alpha therapies (TATs) and combination programs
between Fusion's TATs and AstraZeneca's
DNA Damage Response Inhibitors (DDRis)
and immuno-oncology agents. The Company recently
received IND clearance for FPI-2068, the first novel
TAT under the collaboration, which targets EGFR-cMET.
Fusion has also entered into a collaboration with Merck to evaluate
FPI-1434 in combination with Merck's KEYTRUDA®
(pembrolizumab) in patients with solid tumors
expressing IGF-1R. To support Fusion's growing pipeline of
TATs, the Company has signed strategic actinium supply
agreements with TRIUMF, Niowave, Inc.
and BWXT Medical.
Contact:
Amanda
Cray
Senior Director of Investor Relations &
Corporate Communications
(617) 967-0207
cray@fusionpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-upcoming-investor-conferences-301981379.html
SOURCE Fusion Pharmaceuticals